NTRK fusion events and targeted treatment of advanced radioiodine refractory thyroid cancer

PURPOSE: Pathogenic fusion events involving neurotrophic receptor tyrosine kinase (NTRK) have been described in ~ 2% of differentiated thyroid cancer (DTC). The selective tropomyosin receptor kinase (TRK) inhibitors entrectinib and larotrectinib have been approved in a tumor agnostic manner based on...

Descripción completa

Detalles Bibliográficos
Autores principales: Koehler, Viktoria Florentine, Achterfeld, Josefine, Sandner, Natalie, Koch, Christine, Wiegmann, Jonas Paul, Ivanyi, Philipp, Käsmann, Lukas, Pusch, Renate, Wolf, Dominik, Chirica, Mihaela, Knösel, Thomas, Demes, Melanie-Christin, Kumbrink, Joerg, Vogl, Thomas J., Meyer, Gesine, Spitzweg, Christine, Bojunga, Joerg, Kroiss, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590332/
https://www.ncbi.nlm.nih.gov/pubmed/37548775
http://dx.doi.org/10.1007/s00432-023-05134-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590332/
https://www.ncbi.nlm.nih.gov/pubmed/37548775
http://dx.doi.org/10.1007/s00432-023-05134-x

Ejemplares similares